鼻咽癌中抗PD-L1/PD-1治疗及非编码RNA调控研究进展

Advances in anti-PD-L1/PD-1 therapy and non-coding RNA regulation in nasopharyngeal carcinoma

鼻咽癌(nasopharyngeal carcinoma,NPC)是一种来源于鼻咽上皮组织的头颈部恶性肿瘤,临床难点为晚期或复发患者的治疗,目前研究表明免疫治疗对患者有效。程序性死亡配体1(programmed death ligand 1,PD-L1)在NPC组织中表达增加,与T细胞表面的程序性死亡受体1(programmed death receptor 1,PD-1)结合能抑制T细胞的激活,导致NPC免疫逃逸。非编码RNA在调节NPC发生发展中发挥重要作用,寻找能够调节PD-L1/PD-1轴的上游非编码RNA可以为NPC的免疫治疗提供新思路。论文对PD-L1/PD-1轴在NPC免疫治疗中的作用及相关非编码RNA调控的研究进展进行综述。

Nasopharyngeal carcinoma(NPC)is a malignant head and neck tumor type derived from nasopharyngeal epithelium.Successful treatment of patients with advanced or recurrent NPC remains difficult.Recent studies have shown that immunotherapy is effective for these patients.Programmed death ligand 1(PD-L1)is highly expressed in NPC.PD-L1 binding to programmed death receptor 1(PD-1)on the surface of T cells can inhibit T cell activation,leading to immune escape by NPC.Non-coding RNA plays important roles in regulating the occurrence and development of NPC.Searching for upstream ncRNAs that can regulate the PD-L1/PD-1 axis can provide new ideas for immunotherapy of NPC.This article reviews the role of the PD-L1/PD-1 axis in NPC immunotherapy and summarizes progress of research related to ncRNA regulation.